Cemiplimab with liver radiation for breast cancer that spread to the liver
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of a drug called cemiplimab (an immunotherapy that helps your immune system fight cancer) and a type of targeted radiation (Y-90 SIR-Spheres) given directly to liver tumors. It is for people with breast cancer that has spread to the liver and who have already had at least one type of chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic breast cancer that has spread to the liver and have had at least one prior chemotherapy for metastatic disease.
- Your liver tumors must be measurable and take up less than half of your liver.
- You must be in good general health (ECOG performance status 0 or 1) and have adequate kidney, liver, and blood cell function.
- You cannot have had prior immunotherapy (like cemiplimab or similar drugs) in the last 12 months.
- You cannot have an active autoimmune disease or condition that requires strong immune-suppressing medication.
- You must not be pregnant or breastfeeding and agree to use effective birth control during and for at least 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) for people with pancreatic cancer that has spread to other parts of the body. It is for those whose tumors have specific genetic changes (in the SWI/SNF genes) and have only had one prior treatment that was not immunotherapy.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This trial tests a drug called cemiplimab for people with NUT carcinoma that has spread or cannot be removed. The drug aims to shrink tumors or slow their growth.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.